Key Highlights

  • Loss per share was USD 0.34 against an estimate of a USD 0.54 loss.
  • Net loss was USD 28.82 million, against USD 26.69 million a year earlier.
  • Research and development expenses were USD 22.33 million, against USD 22.95 million.
  • Cash and marketable securities were USD 228.9 million at September 30.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) reported a third quarter 2026 loss per share of USD 0.34, against an estimate of a USD 0.54 loss and a USD 0.37 loss in the third quarter of 2025. Net loss was USD 28.82 million, compared with USD 26.69 million.

The loss from operations was USD 31.15 million, against USD 33.73 million. The company reported the figures in its quarterly filing for the period ended September 30, 2026.

Operating Expenses and Investment Income

Research and development expenses were USD 22.33 million, compared with USD 22.95 million. The filing reports azenosertib external development costs of USD 11.44 million, against USD 12.60 million. General and administrative expenses were USD 8.82 million, compared with USD 10.78 million.

Total operating expenses were USD 31.15 million, against USD 33.73 million. Investment and other income, net, was USD 2.46 million, compared with USD 7.04 million.

Nine-Month Results

For the nine months ended September 30, 2026, net loss was USD 106.45 million, compared with USD 101.84 million, and the loss per share was USD 1.41, against USD 1.42. Total operating expenses were USD 113.40 million, against USD 115.42 million.

Research and development expenses for the nine months were USD 86.21 million, against USD 77.81 million, and general and administrative expenses were USD 27.19 million, against USD 29.81 million. The prior-year period included restructuring expenses of USD 7.80 million.

Azenosertib Program and Liquidity

The filing describes the azenosertib clinical development program, including the DENALI Phase 2 trial in platinum-resistant ovarian cancer and the Phase 3 ASPENOVA trial. In April 2026, the company announced that 400mg QD 5:2 was selected as the pivotal monotherapy dose and that recruitment at the 300mg QD 5:2 dose level was discontinued, with approximately 30 patients enrolled per dose group.

The company had cash, cash equivalents and marketable securities of USD 228.9 million as of September 30, 2026, including cash and cash equivalents of USD 24.03 million. It believes these amounts are sufficient to fund operating expenses and Capital Expenditure requirements into the first half of 2028.

The filing states that the company had an accumulated Deficit of USD 1.3 billion as of September 30, 2026. It reports that the company determined there are no conditions or events that raise substantial doubt about its ability to continue as a Going Concern within one year after the date the interim financial statements were issued. The filing also notes that a prototype of a test described in the filing is being used in DENALI Part 2 and in the Phase 3 ASPENOVA clinical trial, and describes DENALI Part 1b as a fully enrolled single-arm study that evaluated azenosertib monotherapy at 400 mg QD 5:2.

Zentalis Pharmaceuticals Q3 2026 Earnings: Key Takeaways

Zentalis Pharmaceuticals reported a third quarter 2026 loss per share of USD 0.34 and a net loss of USD 28.82 million. Research and Development expenses were USD 22.33 million, and cash, cash equivalents and marketable securities were USD 228.9 million.